Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of cancer with 2-deoxyglucose

A glucose and cancer technology, applied in the field of cancer treatment using 2-deoxyglucose, can solve unproven cancer and other problems

Inactive Publication Date: 2006-05-10
THRESHOLD PHARM INC
View PDF30 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, after more than 50 years of research, 2-DG is still not proven to treat cancer in the United States or Europe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of cancer with 2-deoxyglucose
  • Treatment of cancer with 2-deoxyglucose
  • Treatment of cancer with 2-deoxyglucose

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Growth inhibitory activity of 2-deoxy-D-glucose on human non-small cell lung cancer cell lines

[0101] In this example, the inhibitory effect of 2-deoxy-D-glucose (2-DG) on two cell lines obtained from human non-small cell lung cancer (NSCLC) was demonstrated. The human lung cancer cell lines in question are MV522 and NCI-H23, both obtained from tumors exhibiting adenocarcinoma histopathology, ie one of at least three types of NSCLC. The NCI-H23 tumor cell line is available from ATCC (Rockville, MD) and the MV522 cell line was provided by Dr. M.J. Kelner, University of California. at 37°C with 5% CO 2 Cells were cultured in RPMI medium (Nova Tech, Grand Island, NY) in a humid atmosphere. For passaging, at 75cm 2 Cells grown in shake flasks (60-70% confluent) were rinsed with PBS and removed from shake flasks using trypsin (Gibco BRL) prior to passaging. The cells used in the following experiments were centrifuged and washed at 10 5 Cells / ml were resuspended in cell cultur...

Embodiment 2

Evaluation of 2-DG as a Sole Agent and in Combination with Cisplatin and Paclitaxel

[0105]In the murine MV552 xenograft model, the effect of 2-deoxy-D-glucose (2-DG) alone and in combination with cisplatin was tested in a tumor growth delay study and compared with cisplatin alone The effects were compared as follows: 5-6 week old female nude mice weighing about 20 g were purchased from Harlan, Inc. (Madison, WI). Animals were implanted subcutaneously with sleeves of MV522 human tumor carcinoma fragments harvested from tumors grown subcutaneously in nude mouse hosts. When the tumor size was approximately 71 mg (11 days after inoculation), animals were pair-matched into treatment and control groups. Ten tumor-bearing mice were included in each group. Each mouse was ear-marked for follow-up throughout the experiment. The initial dose was given on day 1 after pair matching. The dosing schedule for 2-DG was oral (p.o.), twice daily, every 12 hours, × 5 until the end (twice dai...

Embodiment 3

Oral formulations of 2-DG

[0118] This example illustrates the preparation of a representative pharmaceutical formulation for oral administration.

[0119] A. Dispensing 2-DG into hard shell gelatin capsules containing 100 mg to 1 g of 2-DG; optionally, about 0.5% (w / w) magnesium stearate may be added. Additionally, a mixture of 2-DG and lactose is available in capsules.

[0120] B. Using 2-DG (20.0% to 89.9% wt / wt., depending on the presence and amount of lactose); magnesium stearate (0.9%); starch (8.6%); optionally lactose (0 -69.6%) and PVP (polyvinylpyrrolidone; 0.9%), other raw materials except magnesium stearate were mixed and granulated using water as a granulating liquid. The preparation is then dried, mixed with magnesium stearate and made into tablets with a tablet machine.

[0121] C. Dissolve 2-DG in a mixture of propylene glycol, polyethylene glycol 400, and polysorbate 80; add water; then dispense the resulting mixture into bottles.

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

Compound 2-deoxyglucose can be used to treat cancer, and when administered in therapeutically effective doses, and optionally co-administered with other anticancer drugs, or in combination with surgical resection or radiation therapy, can improve the treatment of patients Effect.

Description

[0001] Cross References to Related Applications [0001] This application claims priority to the following U.S. Provisional Patent Applications serial numbers: 60 / 439,266, filed January 10, 2003; 60 / 458,665 and 60 / 458,846, filed March 28, 2003; 60 / 460,012; and 60 / 496,163, filed August 18, 2003, which are hereby incorporated by reference. Background of the invention [0002] "Cancer" generally refers to any of more than 100 diseases caused by the uncontrolled abnormal growth of cells that can spread to adjacent tissues or other parts of the body. Cancer cells can form solid tumors in which they aggregate together, or they exist as scattered cells, as is the case in leukemia. Normal cell division (regeneration) stops when it reaches maturity, and is only necessary for the replacement of damaged or dead cells. Cancer cells are often called "malignant" because they divide endlessly, eventually crowding out nearby cells and spreading to other parts of the body. The tendency of c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/70A01N43/04
Inventor G·提马思
Owner THRESHOLD PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com